Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Celgene Corporation |
---|---|
Information provided by: | Celgene Corporation |
ClinicalTrials.gov Identifier: | NCT00091624 |
A Phase I Study of CC-5013 in combination with Doxil, Vincristine and Decadron (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma
Condition | Intervention | Phase |
---|---|---|
Multiple Myeloma |
Drug: CC-5013 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety Study |
Official Title: | A Phase I Study of DVd +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Must have adequate bone marrow function: * Absolute neutrophil count > 1,000 cells/mm3 (1.0 x 109/L)
Exclusion Criteria:
Study ID Numbers: | CC-5013-MM-011 |
Study First Received: | September 13, 2004 |
Last Updated: | August 10, 2009 |
ClinicalTrials.gov Identifier: | NCT00091624 History of Changes |
Health Authority: | United States: Food and Drug Administration |
CC-5013 CC5013 Revlimid Lenalidomide Multiple myeloma |
Dexamethasone Immunoproliferative Disorders Blood Protein Disorders Hematologic Diseases Blood Coagulation Disorders Lenalidomide Vascular Diseases Vincristine |
Paraproteinemias Hemostatic Disorders Doxorubicin Multiple Myeloma Hemorrhagic Disorders Lymphoproliferative Disorders Dexamethasone acetate Neoplasms, Plasma Cell |
Neoplasms by Histologic Type Immunoproliferative Disorders Immune System Diseases Antineoplastic Agents Blood Protein Disorders Hematologic Diseases Lenalidomide Vascular Diseases Paraproteinemias |
Hemostatic Disorders Pharmacologic Actions Multiple Myeloma Neoplasms Hemorrhagic Disorders Therapeutic Uses Cardiovascular Diseases Lymphoproliferative Disorders Neoplasms, Plasma Cell |